GlassScriptPhysician profile
Anna H Powell
NPI 1336377423
$5,285.40
in general payments reported to CMS, 2019-2025
34 companies · $782 in 2025
The $782 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $149 · 2021: $1,200 · 2022: $1,421 · 2023: $634 · 2024: $505 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,634.37 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $672.02 | 2021-2025 | |
| Pfizer INC. | $388.53 | 2019-2025 | |
| Amgen INC. | $354.99 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $298.79 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $214.90 | 2019-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $200.00 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.40 | 2020-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.29 | 2019-2024 | Ofev |
| Kvk-Tech, INC. | $160.55 | 2024-2025 | |
| Intuitive Surgical, INC. | $93.71 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $85.11 | 2022-2025 | Imcivree, Imcivree |
| Abbott Laboratories | $81.35 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $73.92 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $73.74 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $57.55 | 2019-2024 | Veozah |
| Eisai INC. | $51.71 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $50.91 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.65 | 2022 | |
| Esperion Therapeutics, INC. | $40.10 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $39.65 | 2021-2022 | |
| Amarin Pharma, INC. | $36.24 | 2021 | |
| Currax Pharmaceuticals LLC | $32.58 | 2025 | Contrave |
| Glaxosmithkline, LLC. | $32.13 | 2019-2021 | |
| Nalpropion Pharmaceuticals LLC | $27.37 | 2019 | |
| Dexcom, INC. | $26.72 | 2023 | Dexcom G6 Transmitter |
| Philips North America LLC | $24.86 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Phathom Pharmaceuticals, INC. | $23.93 | 2024-2025 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $22.08 | 2022 | |
| Genentech USA, INC. | $19.81 | 2019 | |
| Vivus LLC | $18.28 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.94 | 2019 | |
| Cranial Technologies, INC | $15.60 | 2019 | |
| Daiichi Sankyo INC. | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.